

PrECISE

Personalized Engine for Cancer Integrative Study and Evaluation

The aim of PrECISE is to **improve the treatment of patients suffering from prostate cancer** via identification of disease mechanisms and provision of treatment recommendations based on therapeutic biomarker for individual patients.

Main objectives of the PrECISE project:

- Development of a **comprehensive computational methodology**
- Characterization of **intra-tumour heterogeneity**
- Suggestion of **chemotherapy drugs** and **targeted therapies**
- Development into **deployable, easy to use** software tools

The expected outcome of the PrECISE project is the development of a **software framework** serving as a proof of concept, that provides intuitive tools to **deposit, share, analyze** and **visualize molecular and clinical data** to **infer prognosis, elucidate implicated mechanisms** and **recommend therapy** accordingly.

Project Consortium



Contact Information

Technical Lead: Dr. Maria Rodriguez Martinez
IBM Zurich Research Laboratory

Scientific Lead: Prof. Julio Saez-Rodriguez
RWTH Aachen University Hospital

Coordinator: Dr. Klaus-Michael Koch
Technikon Forschungs- und
Planungsgesellschaft mbH
Burgplatz 3a, A-9500 Villach
Tel.: +43 4242 233 55

E-mail: coordination@precise-project.eu
Web: www.precise-project.eu
Twitter: https://twitter.com/PrECISE_H2020

Project number: 668858
Project start: 1st January, 2016
Project duration: 36 months
Total costs: € 5.695.712,50
EC contribution: € 3.090.312,50



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 668858.

This work is supported (in part) by the Swiss State Secretariat for Education, Research and Innovation (SERI) under contract number 15.0324-2. The opinions expressed and arguments employed therein do not necessarily reflect the official views of the Swiss Government.